Bacterial Infections Post-living-donor Liver Transplantation in Egyptian Hepatitis C Virus-cirrhotic Patients: A Single-center Study
Overview
Authors
Affiliations
Aim: To determine risk factors, causative organisms and antimicrobial resistance of bacterial infections following living-donor liver transplantation (LDLT) in cirrhotic patients.
Methods: This prospective study included 45 patients with hepatitis C virus-related end-stage liver disease who underwent LDLT at Ain Shams Center for Organ Transplant, Cairo, Egypt from January 2014 to November 2015. Patients were followed-up for the first 3 mo after LDLT for detection of bacterial infections. All patients were examined for the possible risk factors suggestive of acquiring infection pre-, intra- and post-operatively. Positive cultures based on clinical suspicion and patterns of antimicrobial resistance were identified.
Results: Thirty-three patients (73.3%) suffered from bacterial infections; 21 of them had a single infection episode, and 12 had repeated infection episodes. Bile was the most common site for both single and repeated episodes of infection (28.6% and 27.8%, respectively). The most common isolated organisms were gram-negative bacteria. was the most common organism isolated from both single and repeated infection episodes (19% and 33.3%, respectively), followed by for repeated infections (11.1%), and for single infections (19%). Levofloxacin showed high sensitivity against repeated infection episodes ( = 0.03). , and were multi-drug resistant (MDR). Pre-transplant hepatocellular carcinoma (HCC) and duration of drain insertion (in days) were independent risk factors for the occurrence of repeated infection episodes ( = 0.024).
Conclusion: MDR gram-negative bacterial infections are common post-LDLT. Pre-transplant HCC and duration of drain insertion were independent risk factors for the occurrence of repeated infection episodes.
Wassef M, Ghaith D, Hussien M, El-Shazly M, Yousef R BMC Infect Dis. 2024; 24(1):674.
PMID: 38969966 PMC: 11225324. DOI: 10.1186/s12879-024-09525-4.
Elwakil W, Rizk S, El-Halawany A, Rateb M, Attia A Antibiotics (Basel). 2023; 12(1).
PMID: 36671278 PMC: 9854726. DOI: 10.3390/antibiotics12010077.
Yang L, Si H, Ma M, Fang Y, Jiang Y, Wang J Cancer Cell Int. 2021; 21(1):202.
PMID: 33836753 PMC: 8035785. DOI: 10.1186/s12935-021-01819-w.
Fang L, Gao C, Bai R, Wang H, Du S Cancer Gene Ther. 2020; 28(7-8):875-891.
PMID: 32978504 DOI: 10.1038/s41417-020-0201-z.
The Great ESKAPE: Exploring the Crossroads of Bile and Antibiotic Resistance in Bacterial Pathogens.
Gipson K, Nickerson K, Drenkard E, Llanos-Chea A, Dogiparthi S, Lanter B Infect Immun. 2020; 88(10).
PMID: 32661122 PMC: 7504946. DOI: 10.1128/IAI.00865-19.